Gujarat FDCA Introduces Online Facility For CoPP With QR Code

Mumbai : In order to streamline the process of issuance of WHO-GMP Certification Scheme for Certificate of Pharmaceutical Products (CoPP) through online mode to boost exports, the Gujarat Food and Drug Control Administration (FDCA) has introduced online facility for submission of applications for WHO-GMP CoPP with QR Code for first time in country through its DMLA software.

Since its development in 2011 jointly by Gujarat FDCA and National Informatics Centre (NIC), the DMLA online platform has been able to grant till date manufacturing and sale license online by Gujarat FDCA in the country.

“Gujarat FDCA has started issuing CoPP with QR Code online since the last one week for the first time in the country,” according to Gujarat FDCA Commissioner Dr H G Koshia while talking about the new feature in online platform and how it will be able to boost exports.

He further added, “DMLA online platform has been replicated across the country and has been an incentive for Gujarat drug manufacturers in a major way. Gujarat FDCA has also been able to dispose of applications online related to issuing licenses to wholesalers and retailers in a time bound manner since the introduction of online Extended Licensing Node (XLN) system set up in the state in 2007.

Following Gujarat online licensing model for sales licenses, 16 states replicated the model in the country. There are 40,000 plus retail and wholesale licensees in the state of Gujarat. At the time of introduction of the online system, there were 15,000 registered sale licensees in the state in 2007, which have also been digitised.

With the implementation of the online system, the process is now paperless and less time consuming. It is easier for the regulator and licensee to track the process of scrutiny through a seamless online documentation process till final issuance of license.

Gujarat government has also revised timelines for grant of manufacturing licenses and renewal of licenses to 60 days and that of grant and renewal of sale licenses to 30 days as part of Pharma Vision 2020 under the Right of Citizens to Services for speedy issuance of licenses.

With growing emphasis on boosting SMEs to help meet the regulatory requirements of not only India but also other major markets like US, Europe and Japan, there is an urgent need for the manufacturers who are revised schedule M compliant to upgrade to WHO GMP and those who are WHO GMP compliant to upgrade to US FDA or EDQM compliance.

  • Related Posts

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    New Delhi: Serious legal gaps in the Drugs and Cosmetics Act, 1940, combined with acute shortages of manpower and infrastructure, continue to impede the Central Drugs Standard Control Organisation (CDSCO)…

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    Patna: In a significant ruling that could have far-reaching implications for NDPS drug-related prosecutions involving common pharmaceutical compounds, the Patna High Court has held that Phenothiazine and Promethazine do not…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    IPC releases draft NFI-2026 to promote rational use of medicines

    IPC releases draft NFI-2026 to promote rational use of medicines